Peptic ulcer of the stomach and duodenum. Prevention of duodenal ulcer recurrence after healing of its active form. Conditions associated with excessive secretion of hydrochloric acid (Zollinger-Ellison syndrome). Treatment of gastroesophageal reflux disease. Prevention of relapse of the reflux disease of the esophagus and the occurrence of erosions or ulcers in the course of gastroesophageal reflux disease.
Composition:
1 tabl powl. contains 20 mg or 40 mg famotidine.
Action:
A competitive inhibitor of histamine H receptors2located in the wall of the parietal cells of the stomach. Famotidine inhibits the secretion of hydrochloric acid, also stimulated by food and pentagastrin, and reduces the concentration of pepsin in gastric juice. About 40-50% of the adopted dose is absorbed from the gastrointestinal tract. The maximum concentration after application of the product in a single dose of 40 mg occurs after about 1-3 hours. It is metabolised in the liver via S-oxidation, mainly to the inactive famotidine sulphoxide. T0,5 in adults with normal renal function is on average 2.5-4 h, but prolonged in patients with renal insufficiency. From 25% to 30% of the oral dose is excreted in the urine in unchanged form.
Contraindications:
Hypersensitivity to famotidine or other components of the preparation. Hypersensitivity to other drugs from the group of H receptor antagonists2 in the interview.
Precautions:
Before starting treatment in patients with gastric ulcer, its cancerous character should be excluded (famotidine therapy may mask the symptoms of gastric cancer). Famotidine is mainly excreted through the kidneys, so patients with severe renal insufficiency should reduce the daily dose accordingly. Due to the cochineal red content, the preparation may cause allergic reactions.
Pregnancy and lactation:
The preparation can be used during pregnancy only if absolutely necessary. Breastfeeding women should discontinue famotidine or breastfeeding, since famotidine is excreted in human milk.
Side effects:
Uncommon: fatigue, transient psychiatric disorders such as: depression, confusion, confusion, anxiety, agitation and hallucinations, nausea, vomiting, discomfort or abdominal pain, anorexia, dry mouth, increased liver enzymes, cholestatic jaundice, rash, pruritus, urticaria, anaphylaxis, vasomotor edema and other allergic reactions, arthralgia and muscle pains, muscle cramps. Rarely: pain and dizziness, constipation, diarrhea. Very rare: toxic epidermal necrolysis, atrioventricular block, gynecomastia, which disappears after discontinuation of the drug.
Dosage:
Orally.Peptic ulcer of the stomach and duodenum 40 mg at bedtime for 4-8 weeksPrevention of duodenal ulcer recurrence 20 mg immediately before bedtime.Conditions associated with excessive secretion of hydrochloric acid (Zollinger-Ellison syndrome) Initially 20 mg every 6 hours. Maintenance dosage should be adjusted individually, depending on the patient's condition and response to treatment. The maximum daily dose is 800 mg.Gastroesophageal reflux disease Treatment: 20 mg twice daily for 6-12 weeks. If the disease has erosion or esophageal ulcers: usually 40 mg 2 times a day for 6-12 weeks.Prevention of relapse of the reflux disease of the esophagus and the occurrence of erosions or ulcers in the course of gastroesophageal reflux disease 20 mg twice daily. Patients with severe renal impairment (creatinine clearance less than 10 ml / min) should use the product at a dose of 20 mg at bedtime.
(C)
